The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targeting

被引:100
作者
Dandamudi, Suman [1 ]
Campbell, Robert B. [1 ]
机构
[1] Northeastern Univ, Bouve Coll Hlth Sci, Dept Pharmaceut Sci, Boston, MA 02115 USA
关键词
cancer; chemotherapy; endothelial cell; tumor vasculature; magnetic liposomes; HPLC;
D O I
10.1016/j.biomaterials.2007.07.024
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Chemotherapy is a popular treatment approach against cancer but significant uptake of drugs by normal tissues is still a major limitation. Magnetic drug targeting (MDT) has been used to improve localized drug delivery to interstitial tumor targets. MDT is now being developed to improve drug delivery to tumor vessels. We thus seek to understand the role of magnetite (MAG-C) in drug loading, influence on cytotoxicity and vascular targeting characteristics. The inclusion of MAG-C at lower concentrations (0.5 mg/ml) in cationic liposomes did not alter the efficiency of loading etoposide, but at higher concentrations (2.5 mg/ml) incorporation decreased from 80 +/- 3.4% to 44 +/- 4.26%. MAG-C reduced the incorporation of dacarbazine. The incorporation was significantly lower compared to liposomal etoposide, both in the presence and absence of MAG-C. The incorporation efficiency of vinblastine sulfate in cationic liposomes was similar for low and relatively high MAG-C content; values for incorporation were 21 +/- 0.11 and 23 +/- 2, respectively. Polyethylene-glycol improved the efficiency of loading chemotherapeutic agents regardless of drug type. Additionally, cytotoxicity and tumor vascular targeting characteristics of liposome therapeutics were not influenced by MAG-C. The components used to prepare magnetic liposomes for MDT should be optimized for maximum therapeutic benefit. Published by Elsevier Ltd.
引用
收藏
页码:4673 / 4683
页数:11
相关论文
共 61 条
[1]   Magnetic drug targeting - Biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment [J].
Alexiou, C ;
Jurgons, R ;
Schmid, RJ ;
Bergemann, C ;
Henke, J ;
Erhardt, W ;
Huenges, E ;
Parak, F .
JOURNAL OF DRUG TARGETING, 2003, 11 (03) :139-149
[2]   Magnetic drug targeting: biodistribution and dependency on magnetic field strength [J].
Alexiou, C ;
Schmidt, A ;
Klein, R ;
Hulin, P ;
Bergemann, C ;
Arnold, W .
JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 2002, 252 (1-3) :363-366
[3]  
Alexiou C, 2000, CANCER RES, V60, P6641
[4]  
Atallah Ehab, 2005, Curr Treat Options Oncol, V6, P185
[5]   In vivo heating of magnetic nanoparticles in alternating magnetic field [J].
Babincová, M ;
Altanerová, V ;
Altaner, C ;
Cicmanec, P ;
Babinec, P .
MEDICAL PHYSICS, 2004, 31 (08) :2219-2221
[6]   Principles of magnetodynamic chemotherapy [J].
Babincová, M ;
Leszczynska, D ;
Sourivong, P ;
Babinec, P ;
Leszczynski, J .
MEDICAL HYPOTHESES, 2004, 62 (03) :375-377
[7]   Laser triggered drug release from magnetoliposomes [J].
Babincová, M ;
Sourivong, P ;
Chorvát, D ;
Babinec, P .
JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 1999, 194 (1-3) :163-166
[8]   AC-magnetic field controlled drug release from magnetoliposomes:: design of a method for site-specific chemotherapy [J].
Babincová, M ;
Cicmanec, P ;
Altanerová, V ;
Altaner, C ;
Babinec, P .
BIOELECTROCHEMISTRY, 2002, 55 (1-2) :17-19
[9]  
Babincová M, 2000, Z NATURFORSCH C, V55, P278
[10]  
Bulte JWM, 2003, METHOD ENZYMOL, V373, P175